# Edoxaban Drug Interaction Potential

**Pharmacodynamic Interactions**
The concurrent use of edoxaban with other anticoagulants, antiplatelet agents, and nonsteroidal anti-inflammatory agents is expected to increase the risk of bleeding in comparison to use of edoxaban alone.

**Pharmacokinetic Interactions**
The absorption of edoxaban is mediated by P-glycoprotein (P-gp). P-gp inhibitors can increase the absorption of edoxaban, increasing both AUC and Cmax. Conversely, P-gp inducers can reduce the absorption of edoxaban, decreasing AUC and Cmax.

It is possible that administration of edoxaban two hours prior to any P-gp inhibitor or inducer may reduce or eliminate the impact of the interaction, but there is insufficient evidence at this time to make this conclusion definitively.

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Examples (based on human <em>in vivo</em> data[^1])</th>
<th>Known or Probable Effect</th>
<th>US PI Recommendation</th>
<th>UW Medicine Suggested Management Guidelines[^2]</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-gp inhibitors</td>
<td>alfentanil, amiodarone*, azithromycin, carvedilol, clarithromycin, cobicistat, conivaptan, cyclosporine*, diltiazem, dronedarone*, duloxetine, erythromycin*, fenofibrate, grapefruit, all HIV protease inhibitors, itraconazole, ivacaftor, ketoconazole*, lapatinib, lomitapide, mefloquine, nicardipine, nifedipine, posaconazole, progesterone, propafenone, quinidine*, quinine, ranolazine, sunitinib, tacrolimus, tamoxifen, telithromycin, ticagrelor, tolvaptan, vemurafenib,</td>
<td>significant increase in edoxaban concentration (AUC and Cmax)</td>
<td>AF: Do not reduce dose of edoxaban</td>
<td>AVOID USE</td>
</tr>
</tbody>
</table>

[^1]: Data from [Clinical Pharmacology](https://depts.washington.edu/anticoag/home)
[^2]: [Guidelines](https://depts.washington.edu/anticoag/home)
| **P-gp inducers** | **Carbamazepine, dexamethasone, pentobarbital, phenobarbital, rifampin*, St. John's wort, tipranavir** | **Significant reduction in edoxaban concentration (AUC and Cmax)** | **Avoid use with rifampin** | **AVOID USE** |


(2) based on probable effects of edoxaban, taking into consideration known characteristics of the precipitant drug according to human *in vivo* data

**Source URL (modified on 01/29/2019 - 12:40):**
https://depts.washington.edu/anticoag/home/content/edoxaban-drug-interaction-potential